FDA Clears Point-of-Care MRI System


Evry will soon be commercially available in the US and will provide MRI imaging to patients in critical care settings.

Gustavo Pradilla, MD

Gustavo Pradilla, MD

This article was originally published on HCPLive, part of the HCPLive Network.

The FDA has given 510(k) clearance for Synaptive Medical's Evry, a point-of-care head magnetic resonance imaging (MRI) system designed to provide immediate access to diagnostic imaging for patients in need of emergency care, including potential complications arising from COVID-19, ischemic stroke, neurological damage or potential head trauma.

The device features a mid-field 0.5T superconducting magnet that is small enough to reduce the footprint currently allotted to MRI machines. Evry also includes predefined imaging protocols, automated series planning including volume section, a detachable stretcher to support bedside transfers and a multichannel head coil with patient-specific customized fitting intended to optimize image quality.

Because of its small size, Evry can be delivered without cranes and forgoes yearly cryogen refills, a cryogen pipe and reinforced flooring, providing significant cost-savings for healthcare systems.

“As medical professionals, our goal is to utilize every tool at our disposal that will improve outcomes for our patients in a variety of situations, Gustavo Pradilla, MD, Chief of Neurosurgery, Grady Memorial Hospital, said in a statement. “With the availability of Evry in the US, we will now be able to provide critical diagnostic information in settings beyond where traditional MRIs are offered, which can significantly expedite the speed at which we make actionable decisions that positively impact patient care.”

All of Synaptive’s products, including Evry, can be used independently or with outside systems.

Related Videos
Michael Levy, MD, PhD
Michael Kaplitt, MD, PhD
Michael Kaplitt, MD, PhD
video 4 - "Amyloid Cascade Hypothesis of Alzheimer’s Disease"
Video 3 - "Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease"
Svetlana Blitshteyn, MD, FAAN, director and founder of Dysautonomia Clinic
© 2024 MJH Life Sciences

All rights reserved.